ArchiMed
French private equity fund focused on the healthcare industry.
ArchiMed is an investment firm exclusively dedicated to the healthcare sector, established in 2014. The firm was founded by Denis Ribon, who previously led the healthcare team at 3i, and his former colleagues from 3i, Vincent Guillaumot and Robin Filmer-Wilson, who joined as managing partners. The founding team's extensive background in healthcare investment and direct operational experience within the industry forms the bedrock of the firm's strategic direction. ArchiMed's creation stemmed from the founders' shared vision of a specialized investment house that could deeply understand and accelerate growth within healthcare companies.
The firm operates with a distinct focus on partnering with companies in the European and North American mid-cap healthcare markets. Its investment strategy is centered on acquiring majority stakes in businesses operating within sectors such as biopharma and outsourced services, medical devices, life sciences, diagnostics, and health IT. ArchiMed's approach is hands-on, leveraging its specialized knowledge to drive both organic and inorganic growth in its portfolio companies, often through international expansion and strategic acquisitions. The firm manages a series of buy-and-build investment funds, raising capital from a global base of institutional investors. Revenue is generated through management fees on committed capital and carried interest on investment profits, a standard model in the private equity industry.
ArchiMed's core service is the management of its private equity funds, MED I, MED II, and the latest, MED Platform II, which closed at €3.5 billion. A key differentiator is the firm’s trans-Atlantic presence, with offices in Lyon and New York, allowing it to effectively execute its strategy across key healthcare markets. The firm prides itself on a decentralized, entrepreneurial partnership model and a commitment to sustainability, being a signatory of the Principles for Responsible Investment. This operational and ethical framework supports its primary objective of building leading global healthcare companies through strategic capital allocation and sector-specific expertise.
Keywords: private equity, healthcare investment, buy-and-build, medical devices, life sciences, diagnostics, mid-cap, biopharma, institutional investors, asset management